Wellington Management Group LLP Sells 181,267 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Wellington Management Group LLP lowered its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 20.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 718,226 shares of the company's stock after selling 181,267 shares during the quarter. Wellington Management Group LLP owned approximately 0.71% of Neurocrine Biosciences worth $82,754,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also made changes to their positions in the company. Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in Neurocrine Biosciences by 0.8% during the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 11,436 shares of the company's stock valued at $1,574,000 after acquiring an additional 90 shares in the last quarter. Fifth Third Bancorp boosted its stake in shares of Neurocrine Biosciences by 14.7% during the 2nd quarter. Fifth Third Bancorp now owns 716 shares of the company's stock valued at $99,000 after buying an additional 92 shares during the period. Total Clarity Wealth Management Inc. grew its holdings in shares of Neurocrine Biosciences by 4.3% during the 2nd quarter. Total Clarity Wealth Management Inc. now owns 2,433 shares of the company's stock valued at $335,000 after acquiring an additional 100 shares in the last quarter. Commerce Bank raised its holdings in shares of Neurocrine Biosciences by 2.6% during the third quarter. Commerce Bank now owns 4,199 shares of the company's stock worth $484,000 after acquiring an additional 108 shares in the last quarter. Finally, Caprock Group LLC boosted its position in Neurocrine Biosciences by 7.0% during the second quarter. Caprock Group LLC now owns 1,669 shares of the company's stock valued at $230,000 after purchasing an additional 109 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company's stock.

Neurocrine Biosciences Trading Down 0.6 %

NBIX stock traded down $0.74 during trading on Wednesday, reaching $128.22. 725,287 shares of the stock were exchanged, compared to its average volume of 868,371. Neurocrine Biosciences, Inc. has a twelve month low of $110.95 and a twelve month high of $157.98. The company has a market capitalization of $12.98 billion, a P/E ratio of 34.57 and a beta of 0.34. The stock has a 50 day simple moving average of $120.91 and a 200-day simple moving average of $130.82.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. StockNews.com lowered Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a report on Friday, November 1st. Royal Bank of Canada reduced their target price on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a "sector perform" rating for the company in a research note on Friday, October 4th. HC Wainwright restated a "buy" rating and set a $190.00 price target on shares of Neurocrine Biosciences in a research note on Friday, November 1st. Barclays reduced their price objective on shares of Neurocrine Biosciences from $180.00 to $160.00 and set an "overweight" rating for the company in a research note on Monday, September 9th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a report on Monday, September 16th. Five investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Neurocrine Biosciences has an average rating of "Moderate Buy" and a consensus price target of $163.91.

Insider Activity

In other news, insider Jude Onyia sold 2,331 shares of Neurocrine Biosciences stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $126.29, for a total transaction of $294,381.99. Following the sale, the insider now directly owns 15,449 shares in the company, valued at approximately $1,951,054.21. The trade was a 13.11 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.30% of the stock is currently owned by company insiders.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.